Overview

The Efficacy of Hyperbaric Oxygen-assisted Treatment for ASUC and Refractory IBD

Status:
ENROLLING_BY_INVITATION
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The Department of Gastroenterology plans to conduct a randomized controlled study on the efficacy analysis of hyperbaric oxygen-assisted treatment for acute severe ulcerative colitis and refractory inflammatory bowel disease. The research design is a randomized, controlled study. The objective is to compare the clinical remission rate, clinical response rate, endoscopic remission rate, and endoscopic response rate between patients with acute severe ulcerative colitis (ASUC) and refractory inflammatory bowel disease (IBD) treated with hyperbaric oxygen therapy (HBOT) as an adjuvant and those treated with standard treatment regimens. This study aims to provide clear evidence for the use of HBOT as an adjuvant treatment for ASUC and refractory IBD.
Phase:
NA
Details
Lead Sponsor:
Xijing Hospital of Digestive Diseases
Treatments:
Hyperbaric Oxygenation